🏥DR. PING DAI: ACADEMIC AND PROFESSIONAL PROFILE
🎓EARLY ACADEMIC PURSUITS
Dr. Ping Dai’s journey in medicine began with a Diploma of Higher Education in Clinical Medicine from Harbin University, followed by a Bachelor’s degree at Qiqihar Medical University. She excelled further with an Outstanding Master’s Degree in Oncology from Shihezi University, and culminated her academic path with a Doctorate in Molecular Radiation Oncology (Dr. Med, Magna Cum Laude) from the prestigious Heidelberg University in Germany—underscoring a profound commitment to academic excellence and clinical innovation.
đź©şPROFESSIONAL ENDEAVORS
With over a decade of clinical and research experience, Dr. Dai currently serves as Assistant Director at the Shanghai Fourth People’s Hospital Affiliated to Tongji University. Her career spans multiple critical roles—oncologist, clinical researcher, and international doctoral candidate at the German Cancer Research Centre (DKFZ)—fusing global perspectives with localized healthcare innovation.
🔬CONTRIBUTIONS AND RESEARCH FOCUS ON BIOMARKERS IN CANCER THERAPY
Dr. Dai’s research centers on radiation oncology, immunotherapy-related thyroid dysfunction, and tumor treating fields (TTFields). Notably, her recent studies explore PD-1/PD-L1 inhibitor-induced thyroid dysfunction as a biomarker for efficacy in advanced lung cancer therapy, published in BMC Cancer and Heliyon. She also leads groundbreaking simulation research on electrodynamic tumor interactions, merging clinical oncology with bioengineering insight.
🌍IMPACT AND INFLUENCE
Dr. Dai’s cross-continental experience—from China to Germany—bridges Eastern and Western oncology practices. Her insights contribute to both clinical protocol improvements and space-radiation biology, collaborating with institutions such as the European Space Agency and Heidelberg Ion Beam Therapy Center. She plays a vital role in shaping translational cancer science and space medicine.
🏆ACADEMIC CITES, ACCOLADES AND RECOGNITION
-
Lead or corresponding author in high-impact journals: Cancer Letters (IF 9.7), APL Bioengineering (IF 6.6), and Frontiers in Oncology.
-
Honored with Outstanding Master’s Graduate award.
-
Latin honors “Magna Cum Laude” for doctoral studies in Germany.
-
Recognized as equal-first author and corresponding author in multiple prestigious publications.
🏆LEGACY AND FUTURE CONTRIBUTIONS
Dr. Dai is establishing a legacy of translational research at the intersection of radiation therapy, immunology, and biomarker discovery. Her future pursuits aim to:
-
Advance predictive markers for immunotherapy outcomes.
-
Explore MSC-based interventions against radiation-induced myelotoxicity.
-
Lead multinational clinical collaborations in cancer therapy and space radiation countermeasures.
🧬CONCLUSION
Dr. Ping Dai is an emerging force in molecular oncology and translational medicine. With a rich academic foundation, strong clinical acumen, and a forward-thinking research vision, she is contributing impactful solutions to global oncology and radiobiology challenges.